Lexaria Bioscience Corp. (LEXX)

Market Cap	17.54M
Revenue (ttm)	525,923
Net Income (ttm)	-9.38M
Shares Out	19.48M
EPS (ttm)	-0.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,059
Open	0.8600
Previous Close	0.8552
Day's Range	0.8552 - 0.9200
52-Week Range	0.8200 - 4.3800
Beta	0.89
Analysts	Strong Buy
Price Target	5.00 (+455.56%)
Earnings Date	Jul 15, 2025

About LEXX

Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company’s DehydraTECH is used with a range of active molecules, including...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: LEXX
• Website: https://lexariabioscience.com

Financial Performance

In 2024, Lexaria Bioscience's revenue was $464,278, an increase of 105.24% compared to the previous year's $226,208. Losses were -$5.80 million, -13.05% less than in 2023.

Analyst Summary

According to one analyst, the rating for LEXX stock is "Strong Buy" and the 12-month stock price target is $5.0.

Price Target

$5.0

(455.56% upside)

Analyst Consensus: Strong Buy